相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
Josiah An et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
Letizia Gianoncelli et al.
ANTICANCER RESEARCH (2020)
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
Yuki Ozaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2020)
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
Ryo Morita et al.
LUNG CANCER (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients
Peng Song et al.
THORACIC CANCER (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer et al.
NATURE MEDICINE (2020)
A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy inKRAS-Mutant Advanced Lung Adenocarcinoma
Luochengling Xiang et al.
FRONTIERS IN ONCOLOGY (2020)
Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
Qiong Lyu et al.
CANCER CONTROL (2020)
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Jang Ho Cho et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
Beung-Chul Ahn et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
Rui Zhang et al.
POSTGRADUATE MEDICINE (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway
Xufu Wang et al.
MOLECULAR IMMUNOLOGY (2019)
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun et al.
LUNG CANCER (2019)
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
Daniel P. Hollern et al.
CELL (2019)
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
Nicolas Guibert et al.
LUNG CANCER (2019)
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer
Terry L. Ng et al.
CANCER (2019)
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review
Gilbert Lazarus et al.
ONCOLOGY REVIEWS (2019)
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
Marina Chiara Garassino et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Daichi Fujimoto et al.
LUNG CANCER (2018)
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Shu-Yung Lin et al.
JOURNAL OF CANCER (2018)
TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
Wenjing Xiao et al.
EBIOMEDICINE (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (vol 350, aad8366, 2015)
E. M. Van Allen
SCIENCE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
分享论文
